超声造影监测原发性肝癌射频消融术的疗效

目的 观察对比剂超声造影（contrast-enhanced ultrasound,CEUS）成像技术对原发性肝癌的诊断价值,以及对肝癌射频消融术治疗效果的评价.方法 适合行射频消融治疗的46例原发性肝癌患者,观察射频消融术前普通超声、CT与CEUS的差别;同时以CT作为标准,对比射频消融术后行CEUS的价值.结果 CEUS与CT检查对原发性肝癌术前诊断价值基本相同,两者的阳性似然比分别为1.26和1.31,敏感度、特异度分别为97%、91%和23%、31%,而灰阶超声检查诊断原发性肝癌的阳性似然比为0.99,敏感度、特异度分别为76%和23%与前两者相比较稍差.射频消融术后CEUS对残存病灶诊断的敏感度和特异度分别为60%和90%,阳性似然比6.18,阴性似然比为0.44,与CT相比差异有统计学意义（P=0.012）.所有患者随访1～9个月,平均5个月,目前均存活;术后1个月射频消融灶周围肿瘤残留3例（6.5%）;术后3、6、9个月复发率分别为8.7%（4/46）、11%（5/46）、11%（5/46）.结论 CEUS与CT结合对诊断原发性肝癌和射频消融术后的复查具有实际应用价值.

Contrast enhanced ultrasound in the evaluation of hepatocellular carcinoma (HCC) after percutaneous radiofrequence ablation

Objective To evaluate contrast-enhanced ultrasound (CEUS) for the diagnosis and follow-up of hepatocellular carcinoma ( HCC) patients after percutaneous radiofrequence ablation ( RFA). Methods The data of 46 HCC cases were reviewed in our study. Results of contrast enhanced computed tomography (CT) , ultrasound contrast agent sonography and grey ultrasound were compared with each other pre- and after percutaneous radiofrequence ablation. Results Contrast agent ultrasound imaging had the same value with CT in preoperative diagnosis of HCC, with postive likelihood ratio of 1.26 and 1.31, respectively,sensitivity of 97% and 91% and specificity of 23% and 31% respectively. For grey ultrasound the positive likelihood ratio was 0.99, sensitivity and specificity was 76% and 23% respectively. The sensitivity and specificity of contrast-enhanced ultrasound after percutaneous radiofrequence ablation was 60% and 90% respectively, and the postive likelihood ratio and negative likelihood ratio was 6. 18 and 0. 44 respectively. The difference was significant while compared with CT (P = 0. 012). All cases were followed-up from 1 to 9 months, and all were alive with recurrence found by contrast-enhanced ultrasound in 3 cases. Conclusions Contrast agent ultrasound imaging is sensitive and effective in the diagnosis of HCC and follow-up after percutaneous radiofrequence ablation.